Hiroshi Yabuki1, Shohei Wakao2, Yoshihiro Kushida2, Mari Dezawa2, Yoshinori Okada1. 1. 1 Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, Japan. 2. 2 Department of Stem Cell Biology and Histology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Abstract
Posttransplantation lung ischemia-reperfusion (IR) injuries affect both patient survival and graft function. In this study, we evaluated the protective effects of infused human multilineage-differentiating stress-enduring (Muse) cells, a novel, easily harvested type of nontumorigenic endogenous reparative stem cell, against acute IR lung injury in a rat model. After a 2-h warm IR injury induction in a left rat lung, human Muse cells, human mesenchymal stem cells (MSCs), and vehicle were injected via the left pulmonary artery after reperfusion. Functionality, histological findings, and protein expression were subsequently assessed in the injured lung. In vitro, we also compared human Muse cells with human MSCs in terms of migration abilities and the secretory properties of protective substances. The arterial oxygen partial pressure to fractional inspired oxygen ratio, alveolar-arterial oxygen gradient, left lung compliance, and histological injury score on hematoxylin-eosin sections were significantly better in the Muse group relative to the MSC and vehicle groups. Compared to MSCs, human Muse cells homed more efficiently to the injured lung, where they suppressed the apoptosis and stimulated proliferation of host alveolar cells. Human Muse cells also migrated to serum from lung-injured model rats and produced beneficial substances (keratinocyte growth factor [KGF], hepatocyte growth factor, angiopoietin-1, and prostaglandin E2) in vitro. Western blot of lung tissue confirmed high expression of KGF and their target molecules (interleukin-6, protein kinase B, and B-cell lymphoma-2) in the Muse group. Thus, Muse cells efficiently ameliorated lung IR injury via pleiotropic effects in a rat model. These findings support further investigation on the use of human Muse cells for lung IR injury.
Posttransplantation lung ischemia-reperfusion (IR) injuries affect both patient survival and graft function. In this study, we evaluated the protective effects of infused human multilineage-differentiating stress-enduring (Muse) cells, a novel, easily harvested type of nontumorigenic endogenous reparative stem cell, against acute IR lung injury in a rat model. After a 2-h warm IR injury induction in a left rat lung, human Muse cells, human mesenchymal stem cells (MSCs), and vehicle were injected via the left pulmonary artery after reperfusion. Functionality, histological findings, and protein expression were subsequently assessed in the injured lung. In vitro, we also compared human Muse cells with human MSCs in terms of migration abilities and the secretory properties of protective substances. The arterial oxygen partial pressure to fractional inspired oxygen ratio, alveolar-arterial oxygen gradient, left lung compliance, and histological injury score on hematoxylin-eosin sections were significantly better in the Muse group relative to the MSC and vehicle groups. Compared to MSCs, human Muse cells homed more efficiently to the injured lung, where they suppressed the apoptosis and stimulated proliferation of host alveolar cells. Human Muse cells also migrated to serum from lung-injured model rats and produced beneficial substances (keratinocyte growth factor [KGF], hepatocyte growth factor, angiopoietin-1, and prostaglandin E2) in vitro. Western blot of lung tissue confirmed high expression of KGF and their target molecules (interleukin-6, protein kinase B, and B-cell lymphoma-2) in the Muse group. Thus, Muse cells efficiently ameliorated lung IR injury via pleiotropic effects in a rat model. These findings support further investigation on the use of human Muse cells for lung IR injury.
The issue of lung ischemia–reperfusion (IR) injury during the acute phase after lung
transplantation is critically important. Not only is IR injury the main cause of primary
graft failure[1,2], it is also associated with impaired lung function during the chronic phase[3,4]. Accordingly, a reduction in the incidence of lung IR injury will yield better
patient outcomes.In animal models of acute lung injury, mesenchymal stem cells (MSCs) exert beneficial
pleiotropic effects by producing multiple immunomodulatory and antiapoptotic substances[5]. In a clinical trial, however, the same treatment scheme failed to yield
statistically meaningful efficacy in patients with acute respiratory distress syndrome[6]. This failure may be attributed in part to the nature of MSCs, as only a few cells
remain in the target organ and therefore remain in damaged tissues for short periods of time[7].Multilineage-differentiating stress-enduring (Muse) cells are stress-tolerant,
nontumorigenic endogenous pluripotent-like stem cells[8] that can be harvested from the connective tissues of various organs, the peripheral
blood, and the bone marrow[9]. Additionally, Muse cells comprise small proportions of commercially available
cultured fibroblasts and MSCs and can be isolated from these populations[10]. These self-renewable cells, which exhibit triploblastic differentiation abilities,
are positive for stage-specific embryonic antigen-3 (SSEA-3), a pluripotent surface marker
expressed on human embryonic stem cells, fertilized eggs, and epiblast stem cells[8,10,11]. Regarding safety, Muse cells exhibit low telomerase activity, do not form teratomas
when transplanted in vivo, and comprise approximately 0.03% of bone marrow transplantation population[8,12]. Regarding feasibility for clinical applications, an approximately 30 mL volume of
human bone marrow (BM) aspirate yields 1 million Muse cells by day 3[7]. In recent studies involving animal models of muscle damage[8], stroke[13], liver damage[14,15], and chronic kidney disease[16], intravenously or locally injected Muse cells actively migrated to and preferentially
engrafted into damaged tissues, spontaneously differentiated into tissue-compatible cells in
response to the microenvironment, and facilitated structural and functional recovery[8]. Recent publications also reported that the trophic effects of Muse cells facilitated
tissue repair in animal models of diabetes mellitus–related skin ulcers[17,18]. Kinoshita et al.[17] showed that Muse cells secreted several substances involved in wound healing such as
hepatocyte growth factor (HGF), stem cell–derived factor 1, and epidermal growth factor
(EGF); these substances contributed to repair of skin ulcers. This suggests Muse cells have
wound healing–promoting effects, and therefore, we hypothesize Muse cells could attenuate
lung IR injury through the secreted substances. Importantly, Muse cells express factors
related to stress tolerance and immunomodulation[19,20] and may therefore exert their ability in the severe conditions such as lung IR
injury, particularly during actively progressing inflammation, apoptosis, and tissue
destruction associated with the acute phase. In the present study, we evaluated the
therapeutic effects of human Muse cells on acute phase lung IR injuries in a rat model.
Materials and Methods
Preparation of Human Muse Cells
Human BM derived MSCs (BM-MSCs) purchased from Lonza Japan (Tokyo, Japan) were cultured
at 37 °C in low-glucose Dulbecco’s modified Eagle’s medium (DMEM; Life Technologies,
Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS; Sigma-Aldrich Corporation, St.
Louis, MO, USA) and 0.1 mg/mL kanamycin (Life Technologies) in a 10-cm dish under a 5%
CO2 atmosphere. Human MSCs from the seventh to eighth subcultures were used
in this study. Muse cells were collected from seventh to eighth subcultures of human MSCs
and added to buffer solution composed of 44 mL of FluoroBrite™ DMEM (Life Technologies), 5
mL of 5% bovine serum albumin (BSA; Sigma-Aldrich Corporation), and 1 mL of 100 mM
ethylenediaminetetraacetic acid (EDTA; Nacalai tesque, Kyoto, Japan). Cells were incubated
with anti-SSEA-3 antibody (1:1,000; BioLegend, San Diego, CA, USA) as the primary antibody
on ice for 1 h. After incubation with the primary antibody, the samples were centrifuged
at 400× g for 5 min. The supernatant was removed and replaced with 900 μL
buffer. Then, the samples were washed 3 times by gentle pipetting. After washing, the
cells were incubated with fluorescein isothiocyanate (FITC, Jackson Immunoresearch, West
Grove, PA, USA)-conjugated anti-rat immunoglobulin (Ig) M antibody (1:100; Jackson
ImmunoResearch, West Grave, PA, USA) as a secondary antibody on ice for 1 h. After
incubation with the secondary antibody, the samples were washed 3 times and then incubated
with anti-FITC microbeads (1:10; Miltenyi Biotec, Bergisch Gladbach, Germany) on ice for
15 min. After washing twice, SSEA-3-positive cells were collected from human MSCs as Muse
cells by magnetic-activated cell sorting (MACS) using an autoMACS™ Pro Separator (Miltenyi
Biotec). Some cells sorted by MACS were subjected to fluorescence-activated cell sorting
(FACS) using BD FACS Aria™ Flow Cytometer (BD Biosciences, Franklin Lakes, NJ, USA). The
ratio of SSEA-3-positive cells to collected cells was determined. Collected cells
containing >70% of SSEA-3-positive cells were used as Muse cells in this
experiment.
Lung IR Injury Rat Model and Cell Injection
All animal procedures were approved by the Tohoku University Animal Care and Use
Committee and conducted according to the institutional guidelines. Eight-week-old male
Sprague Dawley rats, weighing 250 to 290 g, were purchased from SLC Japan (Hamamatsu,
Japan). After habituation for 1 wk, 9-week-old rats, weighing 290 to 340 g, were
anesthetized with isoflurane (DS Pharma Biomedical Co., Ltd., Osaka, Japan) in a closed
box. Anesthetized rats were endotracheally intubated with a 14-gauge angiocatheter and
placed on a rodent ventilator (Natsume Seisakusho Co., Ltd., Tokyo, Japan) with inspired
room air, at a rate of 80 breaths/min (bpm), and a positive end-expiratory pressure of 2
cm H2O. Anesthesia with isoflurane at a concentration of 1% was maintained
using an anesthetic vaporizer. Rats were fixed in the right lateral decubitus position and
a left posterior lateral thoracotomy through the fifth intercostal space was performed.
After resection of the left pulmonary ligament and left pulmonary hilum, 50 U heparin was
administrated through left azygos vein. At 5 min after heparin administration, the left
pulmonary artery, left pulmonary vein, and left bronchus were separately clamped using
microvascular clips at the end of inspiration. Ischemia was maintained in the left lung
for 120 min by covering with moist gauze at an intrathoracic temperature of 37 °C to 38
°C, using a thermal heat warmer[21]. After 120 min, the microvascular clips were removed and the left lung was
ventilated and reperfused. Phosphate-buffered saline (PBS; vehicle group: 200 μL PBS),
human MSCs (MSC group: 1.5 × 105 cells/200 μL PBS), or human Muse cells (Muse
group: 1.5 × 105 cells/200 μL PBS) were administrated through the left
pulmonary artery using a 30-gauge needle immediately after reperfusion. After bleeding
from the site of vascular access was stopped with a cotton swab, the thoracotomy wound was
closed. After wound closure, ventilation was continued without isoflurane and the 14-gauge
catheter was removed under spontaneous breathing. The animals were maintained without
immunosuppressants for 3 or 5 days.
Functional Assessments
On 3 and 5 days after reperfusion, tracheostomy was performed by inserting a shortened
14-gauge catheter endotracheally under anesthesia with isoflurane. Mechanical ventilation
was started with inspired room air at 80 bpm and a positive end-expiratory pressure of 2
cm H2O. Anesthesia with isoflurane at a concentration of 1% was maintained
using an anesthetic vaporizer. Median sternotomy was performed and the chest wall and
bilateral diaphragms were removed to eliminate the influence during the assessment of
pulmonary functions. Gauzes were placed on the bottom of the thorax to prevent prolapse of
the abdominal organs into the thorax. The right hilum was microscopically dissected and
the right pulmonary artery was ligated with a 3-0 silk braid. After ventilation for 5 min,
arterial blood (1 mL) was collected from the ascending aorta under the following
conditions: fraction of inspired oxygen of 100%, tidal volume of 1 mL/100 g body weight,
80 bpm, and a positive end-expiratory pressure of 2 cm H2O. Arterial blood gas
analysis was conducted using the GASTAT-navi Blood Gas Analyzer (Techno Medica Co., Ltd.,
Yokohama, Japan). The ratio of arterial oxygen partial pressure to fractional inspired
oxygen (P/F ratio) and the alveolar-arterial gradient (A-aDO2 = 713 − arterial
carbon dioxide partial pressure/0.8 − arterial oxygen partial pressure) were
calculated. The right hilum was clamped with forceps. The ventilation pressure at a tidal
volume of 0.5 mL/100 g of body weight was recorded. The left lung compliance was
calculated as ventilation volume (mL)/body weight (g)/ventilation pressure (cm
H2O)[22] (n = 8/group/time point).
Lung Sections
All animals were killed by exsanguination after the measurement of lung compliance. After
resection of the heart–lung block, 4% paraformaldehyde was injected through the trachea at
10 cm H2O and the left lung was fixed in 4% paraformaldehyde for 24 h in 4 °C.
After fixation, the left lung was separated and cut into 6 equal portions from the cranial
to the caudal end. Half of the lung sections were embedded in paraffin and the others were
embedded in optimum cutting temperature compound. The paraffin-embedded sections were cut
to a thickness of 3 μm and cryosections were cut to a thickness of 8 μm.
Histological Assessments
To evaluate the severity of lung IR injury on days 3 and 5, four pathological categories
(intra-alveolar edema, intra-alveolar hemorrhage, capillary congestion, and neutrophil
infiltration) of hematoxylin–eosin (H&E) staining sections were scored on a scale of 0
to 4, where 0 = 0% involvement, 1 = 1% to 25% involvement, 2 = 26% to 50% involvement, 3 =
51% to 75% involvement, and 4 = 76% to 100% involvement, according to a modification of a
previous report[23]. Two observers scored all sections in a blinded manner. The average of 2 scores was
used when the scores of 2 observers were not equal (n = 8/group/time
point).
Preparation for Immunohistochemical Analysis
For immunohistochemical analysis, blocking solution and antibody diluent solution were
prepared according to the following methods. For preparation of blocking solution, 2.5 g
of BSA (Sigma-Aldrich Corporation), 150 μL of Triton X-100 (Nacalai Tesque, Inc., Kyoto,
Japan), and 0.4 g of Block Ace (DS Pharma Biomedical Co., Ltd.) were dissolved in PBS to a
total volume of 50 mL. Antibody diluent solution contained 0.5 g of BSA, 150 μL of Triton
X-100, and 0.1 g of Block Ace was dissolved in PBS for a total 50 mL. Antibody diluent
solution was used for dilution of the primary antibodies, and 0.1% Triton X-100PBS was
used for dilution of the secondary antibodies. The sections were observed under a laser
confocal microscope (C2+; Nikon, Tokyo, Japan).
Antihuman 58K Golgi Antibody Immunostaining
Numbers of human Golgi-positive cells were counted on days 3 and 5 to examine the
existence of the injected cells. Cryosections were blocked by incubating in prepared
blocking solution for 30 min at room temperature and then rabbit anti-human 58K Golgi
antibody (dilution, 1:50; Abcam, Cambridge, UK), as the primary antibody, overnight in 4
°C. After incubation with the primary antibody, the sections were washed 3 times with PBS
for 5 min each and then incubated with Cyanine3 (Cy3)-conjugated donkey anti-rabbit IgG
antibody (1:500; Jackson ImmunoResearch) for 2 h at room temperature. The numbers of human
Golgi-positive cells in the MSC and Muse groups were counted. In addition, the groups
administrated 1.5 × 105 cells of either MSCs or Muse cells (plus 200 μL of PBS)
into intact rats were set. Three sections per animal were observed. The area of each
section was measured, and the number of human Golgi-positive cells was counted. The number
of human Golgi-positive cells per unit area (mm2) was calculated on each
section. The average of 3 sections per animal was calculated and compared among groups.
Lung IR injury groups were assessed on days 3 and 5, and the intact groups were assessed
on day 3 (n = 4/group/time point).
Western Blotting of the Injured Rat Lungs
The injured lung tissue was obtained on day 3 from each group, and 0.1 g of lung tissue
from the lung hilum was homogenized with lysis buffer (20 mM Tris–HCl, 150 mM NaCl, and 1%
Triton X-100) containing protease inhibitor cocktail (Roche Diagnostics Deutschland GmbH,
Mannheim, Germany). After homogenization, the samples were incubated for 10 min on ice.
Protein concentrations were calculated by the Bradford assay using a spectrophotometer.
Afterward, the samples were added to the same volume of sample buffer (30% glycerol, 4%
sodium dodecyl sulfate, 125-mM Tris–HCl at pH 6.8, 100-mM dithiothreitol, 10-mM EDTA, 10%
β-mercaptoethanol, and 0.1% bromophenol blue) and incubated for 10 min at 100 °C.
Extracted proteins (50 μg) were run on either a 10% or 15% SuperSep Ace agarose gel (Wako
Pure Chemical Industries, Ltd., Osaka, Japan) and then transferred to an Immobilon-P
Transfer Membrane (Merck Millipore, Billerica, MA, USA). After blocking with 5% skim milk
(Nacalai Tesque, Kyoto, Japan) for 1 h at 4 °C, the transfer membranes were incubated with
the following primary antibodies diluted in 5% skim milk overnight at 4 °C: mouse
anti-IL-6 antibody (1:2,000; Abcam), goat anti-keratinocyte growth factor (KGF) antibody
(1:2,000; R&D Systems, Inc., Minneapolis, MN, USA), rabbitanti-B-cell lymphoma-2
(Bcl-2) antibody (1:500; Abcam), rabbit anti-phospho-protein kinase B (Akt) antibody
(1:2,000; Cell Signaling Technology, Danvers, MA, USA), and mouse anti-β-actin antibody
(1:10,000; Abcam). After overnight incubation, horseradish peroxidase (HRP)-conjugated
goat anti-mouse IgG antibody (1:10,000; Jackson ImmunoResearch), HRP-conjugated goat
anti-rabbit IgG antibody (1:5,000; Jackson ImmunoResearch), or HRP-conjugated donkey
anti-goat IgG antibody (1:5,000; Jackson ImmunoResearch) were used as secondary
antibodies. The transfer membranes were incubated for 1 h at room temperature with
secondary antibodies diluted in 5% skim milk. After washing, enhanced chemiluminescence
(ECL) reaction was performed using Pierce ECL Plus Western Blotting Substrate (Thermo
Fisher Scientific, Waltham, MA, USA) for 5 min. Images were captured using the ImageQuant
LAS 4000 IR digital imaging system (Fuji Film, Tokyo, Japan). The relative protein
expression was calculated as a ratio to β-actin expression in each sample to compare among
groups (n = 3/group).
Terminal Deoxynucleotidyl Transferase Deoxyuridine Triphosphate Nick End Labeling
(TUNEL) Assay
The numbers of TUNEL-positive cells in the injured lung were counted on days 3 and 5 to
assess cell death in each group. The TUNEL assay was performed using the DeadEnd™
Fluorometric TUNEL System (Promega Corporation, Madison, WI, USA), according to the
manufacturer’s protocol. The number of TUNEL-positive cells was counted in 10 random
fields at 200× magnification in the vehicle, MSC, and Muse groups on days 3 and 5
(n = 4/group/time point).
Proliferation of Type II Alveolar Epithelial Cells
The numbers of alveolar epithelial cells in mitotic phase were counted to assess the
repair activity on days 3 and 5. Using cryosections, antigen retrieval was performed by
microwave treatment (Tris–EDTA at pH 9.0, 80 °C, 20 min). The sections were blocked with
the prepared blocking solution for 30 min at room temperature. Double staining was
performed by incubation overnight at 4 °C with mouse anti-proliferating cell nuclear
antigen (PCNA) antibody (a marker of the active phase of the cell cycle; 1:500; Abcam) and
rabbit anti-pro surfactant protein C (pro SPC; a marker of alveolar type II epithelial
cell; 1:1,000; Merck Millipore) as primary antibodies. Afterward, the samples were
incubated with FITC-conjugated donkey anti-mouse IgG antibody (1:500; Jackson
ImmunoResearch) and Cy3-conjugated rabbit-IgG antibody (1:500; Jackson ImmunoResearch) as
secondary antibodies, respectively, for 2 h at room temperature. The numbers of
PCNA+/ pro SPC+ cells in 10 random fields were counted at 200×
magnification. The total of double-positive cells was calculated to compare among the
vehicle, MSC, and Muse groups on days 3 and 5 (n = 4/group/time
point).
Migration Assay
The migration assay was performed to assess the migration ability of Muse cells and MSCs
to serum of intact rats and lung IR injury model rats using 24-well Biocoat™ Matrigel™
invasion chamber (BD Biosciences). Serum from rats with lung IR injury was collected at 4
h after reperfusion. DMEM (750 μL) containing either 10% lung IR model rat serum or intact
rat serum was added to the lower well of the invasion chamber. Then, 5 × 104
cells of either Muse cells or MSCs in 500 μL of DMEM containing 10% FBS were added to the
upper well. After culture for 22 h at 37 °C under an atmosphere of 5% CO2, the
remaining cells were removed by wiping the inside of the upper wells with cotton swabs.
Invaded cells were fixed with 4% paraformaldehyde for 10 min and stained with H&E.
Migrated cells were counted in 10 random fields at 400× magnification, and averages were
calculated for comparisons.
Comparison of Protective Substance Production Abilities In Vitro
An enzyme-linked immunosorbent assay (ELISA) was performed to measure substance in the
culture supernatant of Muse cells and MSCs. One million Muse cells or MSCs were cultured
in 6 mL of DMEM without FBS for 72 h at 37 °C under an atmosphere of 5% CO2 in
a 6-cm dish. The reason for using the medium without FBS is to eliminate the influence of
cytokines including FBS. The culture supernatant was collected and centrifuged at 400×
g for 5 min to remove dead cells and then used for analysis using
commercial ELISA kits to measure exact concentrations of humanHGF (Abcam), humanangiopoietin-1 (R&D systems, Inc.), humanKGF (R&D systems, Inc.), and humanprostaglandin E2 (PGE2; Abcam). Each assay was performed in triplicate, and averages were
calculated for comparisons.
Statistical Analysis
All data are shown as means ± standard deviations (SD). EZR software
(Version 1.32; Saitama Medical Center, Jichi Medical University, Saitama, Japan) was used
for the statistical analysis[24]. The Mann–Whitney U test was used for 2-group comparisons, whereas
the Kruskal–Wallis test was used for 3-group comparisons. P values were
adjusted using the Holm method, and a value <0.05 was considered statistically
significant.
Results
Effects of Muse Cells on Pulmonary Functions in a Lung IR Injury Model
FACS analyses of Muse cells (i.e., SSEA-3-positive cells[8]) in human BM-MSCs revealed an original frequency of 6.57 ± 0.88%; this value
increased to 73.52 ± 1.70% after MACS enrichment (Fig. 1A). Regarding model rats, those in the Muse
group fared significantly better than the vehicle and MSC groups on both days 3 and 5. On
day 5, the P/F ratio of the Muse group was approximately 3.2- and 1.7-fold higher than
that of the vehicle and MSC groups, respectively (both P < 0.001;
Fig. 1B). Intergroup differences
in A-aDO2 became evident on day 5, with the value in the Muse group equivalent
to roughly 62% and 75% of those in the vehicle and MSC groups, respectively
(P < 0.001; Fig.
1C). Left lung compliance was also significantly higher in the Muse group
relative to other groups on both days 3 and 5 (Fig. 1D). In contrast, the MSC group did not differ
significantly from the vehicle group with respect to the P/F ratio or A-aDO2;
on day 5, the MSC group exhibited better results relative to the vehicle group, although
the extent of the effect was lower than that in the Muse group. These findings suggest
that Muse cells were superior to MSCs with respect to improved pulmonary function in the
acute phase IR-injured lung.
Fig. 1.
(A) Flow cytometry analyses of stage-specific embryonic antigen-3 (SSEA-3) expression
before and after the magnetic-activated cell sorting (MACS) enrichment of
SSEA-3-positive human multilineage-differentiating stress-enduring (Muse) cells from
cultured human mesenchymal stem cells (MSCs). Shown is a representative example of a
flow cytometry analysis of the ratios of SSEA-3-positive cells before and after MACS.
Before enrichment, human MSCs contained 6.57 ± 0.88% Muse cells; this increased to
73.52 ± 1.70% after enrichment. (B–D) Human Muse cells exhibited function-improving
effects in a lung ischemia–reperfusion injury model. A blood gas analysis and left
lung compliance assessment were performed on days 3 and 5. (B) The respective arterial
oxygen partial pressure to fractional inspired oxygen ratios on days 3 and 5 were 65.7
± 24.8 and 91.0 ± 35.6 in the vehicle group, 87.1 ± 26.5 and 170.5 ± 65.7 in the MSC
group, and 141.6 ± 47.9 and 294.7 ± 55.2 in the Muse group. (C) On days 3 and 5, the
respective alveolar-arterial oxygen gradients in the corresponding groups were 565.1 ±
41.5 mmHg and 549.7 ± 41.1 mmHg in the vehicle group, 550.9 ± 28.9 mmHg and 454.9 ±
55.2 mmHg in the MSC group, and 496.9 ± 49.2 mmHg and 340.1 ± 64.3 mmHg in the Muse
group. (D) On days 3 and 5, the respective left lung compliance values in the
corresponding groups were 0.606 ± 0.129 mL/cm H2O/kg and 0.666 ± 0.106
mL/cm H2O/kg in the vehicle group, 0.760 ± 0.043 mL/cm H2O/kg
and 0.894 ± 0.172 mL/cm H2O/kg in the MSC group, and 0.914 ± 0.0118 mL/cm
H2O/kg and 1.015 ± 0.158 mL/cm H2O/kg in the Muse group. Data
are presented as means ± standard deviations; n = 8/group/time point.
*P < 0.05, **P < 0.01, ***P
< 0.001.
(A) Flow cytometry analyses of stage-specific embryonic antigen-3 (SSEA-3) expression
before and after the magnetic-activated cell sorting (MACS) enrichment of
SSEA-3-positive human multilineage-differentiating stress-enduring (Muse) cells from
cultured human mesenchymal stem cells (MSCs). Shown is a representative example of a
flow cytometry analysis of the ratios of SSEA-3-positive cells before and after MACS.
Before enrichment, human MSCs contained 6.57 ± 0.88% Muse cells; this increased to
73.52 ± 1.70% after enrichment. (B–D) Human Muse cells exhibited function-improving
effects in a lung ischemia–reperfusion injury model. A blood gas analysis and left
lung compliance assessment were performed on days 3 and 5. (B) The respective arterial
oxygen partial pressure to fractional inspired oxygen ratios on days 3 and 5 were 65.7
± 24.8 and 91.0 ± 35.6 in the vehicle group, 87.1 ± 26.5 and 170.5 ± 65.7 in the MSC
group, and 141.6 ± 47.9 and 294.7 ± 55.2 in the Muse group. (C) On days 3 and 5, the
respective alveolar-arterial oxygen gradients in the corresponding groups were 565.1 ±
41.5 mmHg and 549.7 ± 41.1 mmHg in the vehicle group, 550.9 ± 28.9 mmHg and 454.9 ±
55.2 mmHg in the MSC group, and 496.9 ± 49.2 mmHg and 340.1 ± 64.3 mmHg in the Muse
group. (D) On days 3 and 5, the respective left lung compliance values in the
corresponding groups were 0.606 ± 0.129 mL/cm H2O/kg and 0.666 ± 0.106
mL/cm H2O/kg in the vehicle group, 0.760 ± 0.043 mL/cm H2O/kg
and 0.894 ± 0.172 mL/cm H2O/kg in the MSC group, and 0.914 ± 0.0118 mL/cm
H2O/kg and 1.015 ± 0.158 mL/cm H2O/kg in the Muse group. Data
are presented as means ± standard deviations; n = 8/group/time point.
*P < 0.05, **P < 0.01, ***P
< 0.001.
Histologic Assessment of H&E-stained Sections
The Muse group had lower values of all parameters and lower rates of intra-alveolar
edema, intra-alveolar hemorrhage, capillary congestion, and neutrophil infiltration
relative to the vehicle and MSC groups on day 3, suggesting that Muse cells promote
remarkable histologic improvements during the early phase after IR injury (Fig. 2A and B). However, only the
reduction of neutrophil infiltration in the Muse group remained significant on day 5,
whereas all other intergroup differences resolved due to improvements in these parameters
in both the vehicle and MSC groups (Fig.
2C). In contrast, none of the histologic parameters differed significantly
between the MSC and vehicle groups on day 3 or 5.
Fig. 2.
Histologic assessment of hematoxylin–eosin (H&E)-stained sections of
ischemia–reperfusion-injured lung tissues. (A) Images of H&E-stained sections
collected on days 3 and 5 at 100× magnification (enlarged images = 200×). Scale bars =
100 μm. (B and C) Histologic parameters, intra-alveolar edema, intra-alveolar
hemorrhage, capillary congestion, and neutrophil infiltration were scored from 0 to 4
on days 3 (B) and 5 (C). The intra-alveolar edema scores on the respective days were
2.94 ± 0.77 and 1.50 ± 0.50, 2.38 ± 0.74 and 1.19 ± 0.35, and 1.19 ± 0.17 and 0.88 ±
0.33 for the vehicle, mesenchymal stem cell, and multilineage-differentiating stress
enduring groups, respectively. The corresponding intra-alveolar hemorrhage scores were
1.88 ± 0.33 and 1.38 ± 0.33, 1.75 ± 0.43 and 1.19 ± 0.24, and 0.94 ± 0.17 and 0.94 ±
0.30, respectively. The corresponding capillary congestion scores were 2.19 ± 0.50 and
1.38 ± 0.33, 1.75 ± 0.25 and 1.44 ± 0.17, and 1.25 ± 0.25 and 1.13 ± 0.22,
respectively. The corresponding neutrophil infiltration scores were 3.19 ± 0.50 and
2.31 ± 0.43, 2.63 ± 0.78 and 2.13 ± 0.54, and 1.38 ± 0.41 and 1.31 ± 0.24,
respectively. Data are presented as means ± standard deviations; n =
8/group/time point. *P < 0.05, **P < 0.01.
Histologic assessment of hematoxylin–eosin (H&E)-stained sections of
ischemia–reperfusion-injured lung tissues. (A) Images of H&E-stained sections
collected on days 3 and 5 at 100× magnification (enlarged images = 200×). Scale bars =
100 μm. (B and C) Histologic parameters, intra-alveolar edema, intra-alveolar
hemorrhage, capillary congestion, and neutrophil infiltration were scored from 0 to 4
on days 3 (B) and 5 (C). The intra-alveolar edema scores on the respective days were
2.94 ± 0.77 and 1.50 ± 0.50, 2.38 ± 0.74 and 1.19 ± 0.35, and 1.19 ± 0.17 and 0.88 ±
0.33 for the vehicle, mesenchymal stem cell, and multilineage-differentiating stress
enduring groups, respectively. The corresponding intra-alveolar hemorrhage scores were
1.88 ± 0.33 and 1.38 ± 0.33, 1.75 ± 0.43 and 1.19 ± 0.24, and 0.94 ± 0.17 and 0.94 ±
0.30, respectively. The corresponding capillary congestion scores were 2.19 ± 0.50 and
1.38 ± 0.33, 1.75 ± 0.25 and 1.44 ± 0.17, and 1.25 ± 0.25 and 1.13 ± 0.22,
respectively. The corresponding neutrophil infiltration scores were 3.19 ± 0.50 and
2.31 ± 0.43, 2.63 ± 0.78 and 2.13 ± 0.54, and 1.38 ± 0.41 and 1.31 ± 0.24,
respectively. Data are presented as means ± standard deviations; n =
8/group/time point. *P < 0.05, **P < 0.01.
Survival of Infused Muse Cells into IR-injured Lungs
When cells were infused into the intact lungs of normal rats via the left pulmonary
artery, the numbers of remaining human MSCs and human Muse cells in the lungs on day 3
were very small and did not differ significantly (Fig. 3A and B). However, when cells were infused into
IR-injured lungs, human Golgi+ cells were observed in many fields, and the
numbers of human Golgi+ cells in the Muse group on day 3 were roughly 12.5- and
9.1-fold higher than those in the normal and MSC groups in which human Golgi+
cells were observed in a few field, respectively (both P < 0.05; Fig. 3A and B). Although the number of
human Muse cells in the injured lung decreased on day 5 relative to day 3, the Muse cell
numbers remained approximately 12.5-fold higher than those in the MSC group
(P < 0.01; Fig.
3B). In contrast to the Muse group, the number of human Golgi+ cells
increased minimally upon infusion into the IR-injured lung in the MSC group relative to
the normal group.
Fig. 3.
Immunostaining with an anti-human 58K Golgi antibody. (A) Human
multilineage-differentiating stress enduring (Muse) cells and human mesenchymal stem
cells (MSCs; 1.5 × 105 cells each) were administered to intact rats and
lung ischemia–reperfusion injury model rats via the left pulmonary artery (scale bars
= 100 μm). (B) Numbers of human Golgi-positive cells/area (mm2) in each
group and at each time point. The respective numbers in the intact rat lung on day 3
were 0.015 ± 0.0026 cells/mm2 and 0.016 ± 0.0055 cells/mm2 in
the MSC and Muse groups. In the injured rat lung on days 3 and 5, the respective
numbers were 0.022 ± 0.0022 cells/mm2 and 0.0095 ± 0.010
cells/mm2 in the MSC group and 0.20 ± 0.12 cells/mm2 and 0.12
± 0.046 cells/mm2 in the Muse group. Data are presented as means ± standard
deviations; n = 4/group/time point. *P < 0.05,
**P < 0.01.
Immunostaining with an anti-human 58K Golgi antibody. (A) Human
multilineage-differentiating stress enduring (Muse) cells and human mesenchymal stem
cells (MSCs; 1.5 × 105 cells each) were administered to intact rats and
lung ischemia–reperfusion injury model rats via the left pulmonary artery (scale bars
= 100 μm). (B) Numbers of human Golgi-positive cells/area (mm2) in each
group and at each time point. The respective numbers in the intact rat lung on day 3
were 0.015 ± 0.0026 cells/mm2 and 0.016 ± 0.0055 cells/mm2 in
the MSC and Muse groups. In the injured rat lung on days 3 and 5, the respective
numbers were 0.022 ± 0.0022 cells/mm2 and 0.0095 ± 0.010
cells/mm2 in the MSC group and 0.20 ± 0.12 cells/mm2 and 0.12
± 0.046 cells/mm2 in the Muse group. Data are presented as means ± standard
deviations; n = 4/group/time point. *P < 0.05,
**P < 0.01.
Western Blotting Analysis of Lung Tissues
Compared with lung tissue of the vehicle and MSC groups, that of the Muse group contained
statistically higher levels of IL-6 (P < 0.05), Bcl-2
(P < 0.05), and Akt proteins (P < 0.01). The
Muse and MSC groups had comparable levels of KGF that were nonsignificantly higher than
those in the vehicle group (Fig.
4).
Fig. 4.
Representative Western blots of lungs subjected to ischemia–reperfusion injury and
harvested on day 3. Each protein expression level was normalized to β-actin. Data are
presented as means ± standard deviations; n = 3/group.
*P < 0.05, **P < 0.01. KGF, keratinocyte
growth factor; IL-6, interleukin-6; Akt, protein kinase B; Bcl-2, B-cell lymphoma
2.
Representative Western blots of lungs subjected to ischemia–reperfusion injury and
harvested on day 3. Each protein expression level was normalized to β-actin. Data are
presented as means ± standard deviations; n = 3/group.
*P < 0.05, **P < 0.01. KGF, keratinocyte
growth factor; IL-6, interleukin-6; Akt, protein kinase B; Bcl-2, B-cell lymphoma
2.
Numbers of Apoptotic Cells in IR-injured Lung
On day 3, the number of TUNEL-positive cells in the Muse group was equivalent to 39% and
46% of the values in the vehicle (P < 0.01) and MSC groups
(P < 0.05), respectively. The number in the Muse group decreased
even further on day 5, corresponding to 19% and 27% of those in the vehicle
(P < 0.001) and MSC groups (P < 0.01),
respectively, suggesting that Muse cells suppressed apoptosis in the IR-injured lung
(Fig. 5A and B). In contrast,
the numbers of TUNEL-positive cells in the vehicle and MSC groups did not differ
significantly at either time point, thus demonstrating the superior apoptosis-suppressive
effects of Muse cells relative to MSCs.
Fig. 5.
(A, B) Injured lung cell apoptosis assessment using terminal deoxynucleotidyl
transferase deoxyuridine triphosphate nick end labeling (TUNEL). (A) TUNEL-positive
cells were counted in 10 randomly selected low-power fields (LPFs) on days 3 and 5.
Scale bars = 50 μm. (B) The numbers of TUNEL-positive cells/10 LPF on days 3 and 5
were compared among groups. The days 3 and 5 numbers were 128.50 ± 27.97 cells/10 LPF
and 102.50 ± 28.26 cells/10 LPF, 109.00 ±1 5.59 cells/10 LPF and 74.50 ± 5.68 cells/10
LPF, and 50.25 ±1 5.19 cells/10 LPF and 19.75 ± 10.03 cells/10 LPF in the vehicle,
mesenchymal stem cell (MSC), and multilineage-differentiating stress enduring (Muse)
groups, respectively. Arrowheads indicate TUNEL-positive cells. Scale bars = 50 μm.
Data are presented as means ± standard deviations (SD);
n = 4/group/time point. *P < 0.05,
**P < 0.01, ***P < 0.001. (C, D)
Proliferating cell nuclear antigen (PCNA) and pro-surfactant protein C (pro-SPC)
immunostaining of lung tissues. (C) Tissues were double stained with antibodies
specific for PCNA and pro-SPC (type II alveolar epithelial cell marker) on days 3 and
5. (D) The numbers of PCNA+/ pro SPC+ double-positive cells in
10 randomly selected LPFs were counted on days 3 and 5: 10.75 ± 7.79 cells/10 LPF,
12.75 ± 7.79 cells/10 LPF, and 37.75 ± 14.36 cells/10 LPF were counted in the vehicle,
MSC, and Muse groups, respectively, on day 3. The corresponding numbers on day 5 were
3.50 ± 3.35 cells/10 LPF, 11.25 ± 8.87 cells/10 LPF, and 31.00 ± 14.82 cells/10 LPF,
respectively. Arrowheads indicate PCNA+/pro SPC+ double-positive
cells. Scale bars = 50 μm. Data are presented as means ± SD;
n = 4/group/time point. * P < 0.05.
(A, B) Injured lung cell apoptosis assessment using terminal deoxynucleotidyl
transferase deoxyuridine triphosphate nick end labeling (TUNEL). (A) TUNEL-positive
cells were counted in 10 randomly selected low-power fields (LPFs) on days 3 and 5.
Scale bars = 50 μm. (B) The numbers of TUNEL-positive cells/10 LPF on days 3 and 5
were compared among groups. The days 3 and 5 numbers were 128.50 ± 27.97 cells/10 LPF
and 102.50 ± 28.26 cells/10 LPF, 109.00 ±1 5.59 cells/10 LPF and 74.50 ± 5.68 cells/10
LPF, and 50.25 ±1 5.19 cells/10 LPF and 19.75 ± 10.03 cells/10 LPF in the vehicle,
mesenchymal stem cell (MSC), and multilineage-differentiating stress enduring (Muse)
groups, respectively. Arrowheads indicate TUNEL-positive cells. Scale bars = 50 μm.
Data are presented as means ± standard deviations (SD);
n = 4/group/time point. *P < 0.05,
**P < 0.01, ***P < 0.001. (C, D)
Proliferating cell nuclear antigen (PCNA) and pro-surfactant protein C (pro-SPC)
immunostaining of lung tissues. (C) Tissues were double stained with antibodies
specific for PCNA and pro-SPC (type II alveolar epithelial cell marker) on days 3 and
5. (D) The numbers of PCNA+/ pro SPC+ double-positive cells in
10 randomly selected LPFs were counted on days 3 and 5: 10.75 ± 7.79 cells/10 LPF,
12.75 ± 7.79 cells/10 LPF, and 37.75 ± 14.36 cells/10 LPF were counted in the vehicle,
MSC, and Muse groups, respectively, on day 3. The corresponding numbers on day 5 were
3.50 ± 3.35 cells/10 LPF, 11.25 ± 8.87 cells/10 LPF, and 31.00 ± 14.82 cells/10 LPF,
respectively. Arrowheads indicate PCNA+/pro SPC+ double-positive
cells. Scale bars = 50 μm. Data are presented as means ± SD;
n = 4/group/time point. * P < 0.05.
Host Alveolar Type II Cell Proliferative Activity
On day 3, the number of PCNA+/pro SPC+-double-positive cells in the
Muse group was approximately 3.5- and 3-fold higher than those in the vehicle and MSC
groups, respectively (both P < 0.05; Fig. 5C and D). On day 5, this number remained
significantly higher in the Muse group only relative to the vehicle group
(P < 0.05; Fig. 5C
and D). The MSC and vehicle groups did not differ significantly at either time
point.
Muse Cell and MSC Migration Assay
Few Muse cells and MSCs migrated toward intact rat serum, and the intergroup difference
was not significant. In contrast, an approximately 10-fold higher number of Muse cells
migrated to the serum of IR injury model rats, compared with MSCs (P <
0.001; Fig. 6). In other words,
Muse cells exhibited a stronger migratory capacity toward serum from IR injury model rats
than did MSCs, but did not tend to migrate toward intact rat serum.
Fig. 6.
Evaluation of the abilities of human multilineage-differentiating stress enduring
(Muse) cells and human mesenchymal stem cells (MSCs) to migrate toward sera from
intact and lung ischemia–reperfusion (IR) injury model rats. Migrated cells were
counted in 10 random high-power fields (HPFs) at 400× magnification, and the averages
were used for comparison. When intact rat serum was used, 1.30 ± 1.00 MSCs and 1.20 ±
0.98 Muse cells were counted per HPF. When serum from IR injury model rats was used,
the corresponding values were 4.40 ± 1.80 cells/HPF and 46.50 ± 10.43 cells/HPF,
respectively. Data are presented as means ± standard deviations. ***P
< 0.001.
Evaluation of the abilities of human multilineage-differentiating stress enduring
(Muse) cells and human mesenchymal stem cells (MSCs) to migrate toward sera from
intact and lung ischemia–reperfusion (IR) injury model rats. Migrated cells were
counted in 10 random high-power fields (HPFs) at 400× magnification, and the averages
were used for comparison. When intact rat serum was used, 1.30 ± 1.00 MSCs and 1.20 ±
0.98 Muse cells were counted per HPF. When serum from IR injury model rats was used,
the corresponding values were 4.40 ± 1.80 cells/HPF and 46.50 ± 10.43 cells/HPF,
respectively. Data are presented as means ± standard deviations. ***P
< 0.001.
Production of Protective Substances from Muse Cells and MSCs In Vitro
Compared with MSCs, Muse cells produced greater amounts of HGF (∼2.8-fold relative to
MSCs; P < 0.01), angiopoietin-1 (∼1.4-fold; P <
0.05), KGF (∼2.4-fold; P < 0.001), and PGE2 (∼5.4-fold;
P < 0.001), according to the results of an ELISA analysis (Fig. 7).
Fig. 7.
Analysis of protective factor production in human multilineage-differentiating stress
enduring (Muse) cells and human mesenchymal stem cells (MSCs). Human cytokine levels
in the supernatants from 72-h cultures containing 106 cells were measured
via enzyme-linked immunosorbent assay. The following respective concentrations were
detected in MSCs and Muse cells: HGF, 169.05 ± 18.66 pg/mL and 472.42 ± 78.09 pg/mL;
angiopoietin-1, 1,428.36 ± 71.86 pg/mL and 1,935.35 ± 140.45 pg/mL; KGF, 94.50 ± 9.47
pg/mL and 230.61 ± 16.30 pg/mL; and prostaglandin E2, 221.88 ± 12.57 pg/mL and
1,206.42 ± 47.56 pg/mL. Data are presented as means ± standard deviations.
*P < 0.05, **P < 0.01, ***P
< 0.001. HGF, hepatocyte growth factor; KGF, keratinocyte growth factor; PGE2,
prostaglandin E2.
Analysis of protective factor production in human multilineage-differentiating stress
enduring (Muse) cells and human mesenchymal stem cells (MSCs). Human cytokine levels
in the supernatants from 72-h cultures containing 106 cells were measured
via enzyme-linked immunosorbent assay. The following respective concentrations were
detected in MSCs and Muse cells: HGF, 169.05 ± 18.66 pg/mL and 472.42 ± 78.09 pg/mL;
angiopoietin-1, 1,428.36 ± 71.86 pg/mL and 1,935.35 ± 140.45 pg/mL; KGF, 94.50 ± 9.47
pg/mL and 230.61 ± 16.30 pg/mL; and prostaglandin E2, 221.88 ± 12.57 pg/mL and
1,206.42 ± 47.56 pg/mL. Data are presented as means ± standard deviations.
*P < 0.05, **P < 0.01, ***P
< 0.001. HGF, hepatocyte growth factor; KGF, keratinocyte growth factor; PGE2,
prostaglandin E2.
Discussion
The present study demonstrates for the first time that (1) Muse cells can more effectively
protect the functions and structure of the lung from IR injury, compared with MSCs; (2)
infused Muse cells remained in the IR-injured lung more efficiently than MSCs; (3)
IR-injured lungs infused with Muse cells had higher levels of substances relevant to tissue
repair, apoptosis prevention, and alveolar fluid clearance; and (4) in vitro, Muse cells
exhibited a stronger migration ability toward sera from IR injury model rats and produced
larger amounts of substances beneficial to an IR-injured lung, compared with MSCs.
Therefore, Muse cell administration is expected to be a useful treatment for lung IR
injury.Muse cells significantly improved the function and structure of the IR-injured lung.
IR-injured lungs in the Muse group expressed higher levels of IL-6, Bcl-2, and Akt, compared
with the other groups, and higher level of KGF, compared with the vehicle group. KGF
restores alveolar fluid clearance, improves vascular permeability[25], and facilitates cell proliferation in the lung[26], and the intracellular factors Bcl-2 and Akt are known to suppress apoptosis[27,28]. Although IL-6 is an inflammatory cytokine[29], it also exerts tissue protective/reparative effects and facilitates cell
proliferation in the lung[30]. Indeed, apoptosis was significantly suppressed in IR-injured lungs in the Muse
group, which could be associated with the higher levels of KGF[31] and IL-6[32] and their antiapoptotic effects mediated through increased Bcl-2/Akt signaling[33]. Additionally, more prominent proliferation of type II alveolar cells, which are
known to play a key role in the repair process after lung injury[34,35], was observed in the Muse group relative to the other groups. KGF[26,36], HGF[37], and IL-6[30] are known to stimulate the proliferation of alveolar epithelial cells, and the higher
expression levels of KGF and IL-6 in the IR-injured lung and better ability of Muse cells to
produce KGF and HGF are thought to have contributed to the increased proliferation of type
II alveolar epithelial cells in the Muse group. Our in vitro study also revealed
significantly increased production of PGE2[38,39], which has anti-inflammatory and protective effects in endothelial tissues, as well
as angiopoietin-1[40,41] and HGF[42], which improve vascular permeability, in Muse cells relative to MSCs. These factors
likely contributed to the amelioration of inflammation and lung edema in the Muse group and
are therefore considered beneficial to the function and structure of the IR-injured lung
(Fig. 8).
Fig. 8.
Schematic diagram of the mechanism by which the pleiotropic effects of human
multilineage-differentiating stress-enduring (Muse) cells promote structural and
functional recovery of the ischemia–reperfusion (IR)-injured lung. The numbers of viable
type I and type II alveolar epithelial cells increased in response to antiapoptotic
effects mediated by B-cell lymphoma-2 and protein kinase B and type II cell
proliferation mediated by IL-6, keratinocyte growth factor (KGF), and hepatocyte growth
factor (HGF). Both processes contributed directly toward improved lung function. KGF
accelerates alveolar fluid clearance and improves vascular permeability together with
angiopoietin-1 and HGF to ameliorate pulmonary edema. Prostaglandin E2 induces vascular
protective effects and mediates anti-inflammatory effects to attenuate inflammation in
the injured lung. In our study, administered human Muse cells conferred all of these
effects, leading to improved lung functionality in the IR injury model rat.
Schematic diagram of the mechanism by which the pleiotropic effects of human
multilineage-differentiating stress-enduring (Muse) cells promote structural and
functional recovery of the ischemia–reperfusion (IR)-injured lung. The numbers of viable
type I and type II alveolar epithelial cells increased in response to antiapoptotic
effects mediated by B-cell lymphoma-2 and protein kinase B and type II cell
proliferation mediated by IL-6, keratinocyte growth factor (KGF), and hepatocyte growth
factor (HGF). Both processes contributed directly toward improved lung function. KGF
accelerates alveolar fluid clearance and improves vascular permeability together with
angiopoietin-1 and HGF to ameliorate pulmonary edema. Prostaglandin E2 induces vascular
protective effects and mediates anti-inflammatory effects to attenuate inflammation in
the injured lung. In our study, administered human Muse cells conferred all of these
effects, leading to improved lung functionality in the IR injury model rat.Significantly more Muse cells than MSCs remained in IR-injured lungs in our model. We
attribute this outcome to two characteristics of Muse cells. First, Muse cells exhibited the
ability to migrate toward damaged tissues[15], as shown in Fig. 6. Notably,
when compared with MSCs, Muse cells more efficiently migrated to sera from IR-injured rats,
suggesting that Muse cells might recognize a substance released from injured lung and
thereby migrate from circulation to the injury site. In contrast, MSCs become passively
trapped in the lung capillaries when infused into the bloodstream[43]. Second, Muse cells are stress tolerant. The harsh microenvironment of the IR-injured
lung contains both proapoptotic and pro-inflammatory cytokines as well as a reactive oxygen species[1,44]. Muse cells, however, produce anti-stress, such as 14-3-3 protein, which plays key
roles in cell cycle regulation and the cellular response to DNA damage following internal or
external injury[19]. Therefore, Muse cells are known to survive for longer durations in stressful
environments, such as acutely inflamed tissues. Accordingly, these cells could address the
major issue facing the use of stem cell/progenitors cells for regenerative medicine, namely
few cells infiltrate and survive in the damaged tissue[44,45]. In the present study, we observed higher numbers of Muse cells, compared to MSCs, in
the IR-injured lungs, suggesting that this is an important mechanism by which Muse cells
efficiently exert their trophic and anti-inflammatory effects and ameliorate the negative
effects of IR injury on the lung function and structure.We note that our study had several limitations. First, we did not induce lung IR injury in
a lung transplantation model; therefore, additional study is needed to confirm the efficacy
of Muse cell therapy in a transplant setting. Second, we did not determine the origins of
substances collected from the IR-injured rat lungs because the antibodies used for Western
blotting detected both human and rat protein isoforms. A lung sample from our model rats
would contain a much larger number of rat lung cells than of infused human cells.
Accordingly, rat lung cells may have been stimulated by infused human cells to secrete
beneficial substances and may therefore be the major source of the analyzed substances.
Finally, additional studies are needed to determine the optimal number of cells to be
administered. Previous studies using rat models of lung IR injury infused 1.0 ×
106 to 1.5 × 107 MSCs per animal[21,45,46], whereas the present study demonstrated that a much smaller number of Muse cells had
beneficial effects on the IR-injured lung. The use of a smaller number of cells may also
have prevented vessel embolization[47,48]. All of these issues warrant further research.
Conclusion
Human Muse cell administration improved the lung functions and histologic damage associated
with an acute phase IR injury in a rat model. Muse cells were found to remain in the
IR-injured lung in larger numbers, compared with MSCs. Lung IR injury amelioration might
therefore be achieved by suppressing apoptosis, stimulating type II alveolar epithelial cell
proliferation, and protecting tissues via the pleiotropic effects of Muse cells.
Authors: Uwe M Fischer; Matthew T Harting; Fernando Jimenez; Werner O Monzon-Posadas; Hasen Xue; Sean I Savitz; Glen A Laine; Charles S Cox Journal: Stem Cells Dev Date: 2009-06 Impact factor: 3.272
Authors: Willem A den Hengst; Jan F Gielis; Judy Y Lin; Paul E Van Schil; Leon J De Windt; An L Moens Journal: Am J Physiol Heart Circ Physiol Date: 2010-09-10 Impact factor: 4.733
Authors: Steven M Fiser; Curtis G Tribble; Stewart M Long; Aditya K Kaza; John A Kern; David R Jones; Mark K Robbins; Irving L Kron Journal: Ann Thorac Surg Date: 2002-04 Impact factor: 4.330
Authors: N S Ward; A B Waxman; R J Homer; L L Mantell; O Einarsson; Y Du; J A Elias Journal: Am J Respir Cell Mol Biol Date: 2000-05 Impact factor: 6.914
Authors: R C King; O A Binns; F Rodriguez; R C Kanithanon; T M Daniel; W D Spotnitz; C G Tribble; I L Kron Journal: Ann Thorac Surg Date: 2000-06 Impact factor: 4.330
Authors: M B Schaefer; A Pose; J Ott; M Hecker; A Behnk; R Schulz; N Weissmann; A Günther; W Seeger; K Mayer Journal: Eur Respir J Date: 2008-07-24 Impact factor: 16.671
Authors: Ahmad Farooq; Courtney M Richman; Sandip M Swain; Rafiq A Shahid; Steven R Vigna; Rodger A Liddle Journal: Gastroenterology Date: 2021-05-26 Impact factor: 22.682